Pfizer pays $180 m for Brisbane company

A Brisbane-based company that invented a smartphone app it says can diagnose COVID-19 and other respiratory illnesses by listening to someone cough has been purchased by Pfizer for nearly $180 million.

ResApp Health Limited uses diagnostic technology developed by Associate Professor Udantha Abeyratne and his research team at the University of Queensland (UQ) to record and analyse a

patient’s coughs on a smartphone.

The app also considers the self-reporting of simple symptoms like a runny nose or fever to diagnose and measure the severity of a range of pulmonary diseases, including asthma and pneumonia.

Pfizer, which is one of the world’s largest bio-pharmaceutical companies, offered to buy ResApp earlier this year when the company announced positive results for its COVID-19 screening test.

You May also like